ASRS: American Society of Retina Specialists

Pavblu, an Eylea biosimilar, shows stable vision outcomes and minimal side effects in real-world use, promising a reliable treatment option for patients.

Step therapy by Medicare Advantage plans was also associated with more injections, although that result fell short of meeting statistical significance standards.

Two presentations discussed the significant care disruptions when there are copay assistance shortages, with patients forgoing effective treatments and turning to lower-cost alternatives with worsening outcomes.

Data from week 156 are favorable and no new safety signals emerged, says researcher.

A new analysis finds that prior authorization for anti-VEGF therapies increases societal costs despite minimal insurer savings, burdening patients, workplaces, and providers.

Ixo-vec reduced anti-VEGF injection frequency and was well tolerated in patients with wet AMD. A phase 3 pivotal trial comparing it with Eylea 2 mg is under way.

Fluid resolution at week 4 seems to translate into longer dosing intervals at week 96 of the PULSAR trial that assessed Eylea HD in patients with neovascular (wet) age-related macular degeneration.

IRX-101, a new antiseptic tested in patients receiving eye injections for macular degeneration, resulted in less pain and fewer adverse events than povidone-iodine.

Small doses of the involuntary nervous system blocker, atropine, may offer a non-invasive treatment for symptomatic vitreous floaters, according to a recent small study.

Results show dosing intervals increasing by two weeks or longer for patients with diabetic macular edema and neovascular (wet) age-related macular degeneration who switch to Eylea HD.

Anti-VEGF and anti-complement therapies work on distinct mechanisms in age-related macular degeneration, and both may be required to treat patients with advanced disease or complex cases.

Extension study results suggest dosing intervals of 20 weeks or more for Eylea HD for diabetic macular edema.

New insights emerge from ongoing analyses of GA studies, enhancing AMD treatment strategies and patient management at Bay Area Retina Associates.

PER-001, delivered through a slow-release, dissolvable implant in the vitreous cavity of the eye, is designed to block endothelin signaling to increase ocular blood flow and prevent vision loss.

Discover new safety insights on Syfovre for geographic atrophy treatment, as Roger A. Goldberg highlights promising long-term data at ASRS 2025.

New findings reveal Syfovre may protect central vision in macular degeneration patients, delaying vision loss and enhancing treatment strategies.

New findings reveal that early treatment with Syfovre significantly improves vision preservation in geographic atrophy patients, according to Robert Goldberg, M.D., MBA, of the Bay Area Retina Associates.

Interest in surgical advancements such as retinal detachment repair is driven by the need for balance within the field and a new generation entering the workforce, according to Gaurav K. Shah, M.D., program chair of ASRS 2025.

A session on a surgery technique to treat macular holes using amniotic membrane transplants will be one of the highlights at the 2025 meeting of the American Society of Retina Specialists, according to Gaurav K. Shah, M.D., program chair of ASRS 2025.

There will be a greater focus on surgical topics at the 2025 meeting of the American Society of Retina Specialists, compared with previous years, which reflects the need for balance within the industry, according to Gaurav K. Shah, M.D., program chair of ASRS 2025.

Surveys of American Society of Retina Specialists members have revealed a preference for physicians’ experiences with new therapies, rather than summaries of clinical trial data, according to Gaurav K. Shah, M.D., program chair of ASRS 2025.

Dante J. Pieramici, M.D., of the California Retina Research Foundation, explains changes made to the Susvimo port delivery system that are designed. to prevent the septum dislodgment that led to Genentech pulling the product off the market.

The two-year study period might not have been long enough to capture tadalafil's effect, which could be positive for dry age-related macular degeneration (AMD) and negative for wet AMD.

Here’s what you missed this week on Managed Healthcare Executive.

Results of the American Society of Retina Specialists annual survey provide insight into opinions of its members and their current and future practice patterns.

Results from retrospective real-world studies presented at American Society of Retina Specialists annual meetiing put the risk of retinal vasculitis from Syfovre at 1 in 1,330 patients. But other results presented at the meeting supplied evidence that Syfovre fends off vision loss caused by geographic atrophy, an advanced form of dry age-related macular degeneration.

Session on diabetic retinopathy includes results from trials of a variety of approaches to retinopathy.

Findings from an analysis of data from the pivotal PHOTON trial didn't show any increased risk of higher intraocular pressure building from injections of the high-dose, 8-mg version of Eylea.

Teleophthalmology enables earlier access to eye care for patients with diabetes, but vulnerable populations often have worse insurance coverage.

But the presenter downplayed the rivalry between the two new treatments for geographic atrophy. “I think we are lucky to have multiple therapies,” saidPaul Hahn, M.D., Ph.D. of NJRetina.